Literature DB >> 27623992

Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.

Martin Schlensog1, Lara Magnus1, Timon Heide1, Julian Eschenbruch1, Florian Steib1, Maximilian Tator1, Vera Kloten1, Michael Rose1, Erik Noetzel2, Nadine T Gaisa1, Ruth Knüchel1, Edgar Dahl1,3.   

Abstract

Secreted frizzled related protein 3 (SFRP3) contains a cysteine-rich domain (CRD) that shares homology with Frizzled CRD and regulates WNT signaling. Independent studies showed epigenetic silencing of SFRP3 in melanoma and hepatocellular carcinoma. Moreover, a tumor suppressive function of SFRP3 was shown in androgen-independent prostate and gastric cancer cells. The current study is the first to investigate SFRP3 expression and its potential clinical impact on non-small cell lung carcinoma (NSCLC). WNT signaling components present on NSCLC subtypes were preliminary elucidated by expression data of The Cancer Genome Atlas (TCGA). We identified a distinct expression signature of relevant WNT signaling components that differ between adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Of interest, canonical WNT signaling is predominant in LUAD samples and non-canonical WNT signaling is predominant in LUSC. In line, high SFRP3 expression resulted in beneficial clinical outcome for LUAD but not for LUSC patients. Furthermore, SFRP3 mRNA expression was significantly decreased in NSCLC tissue compared to normal lung samples. TCGA data verified the reduction of SFRP3 in LUAD and LUSC patients. Moreover, DNA hypermethylation of SFRP3 was evaluated in the TCGA methylation dataset resulting in epigenetic inactivation of SFRP3 expression in LUAD, but not in LUSC, and was validated by pyrosequencing of our NSCLC tissue cohort and in vitro demethylation experiments. Immunohistochemistry confirmed SFRP3 protein downregulation in primary NSCLC and indicated abundant expression in normal lung tissue. Two adenocarcinoma gain-of-function models were used to analyze the functional impact of SFRP3 on cell proliferation and regulation of CyclinD1 expression in vitro. Our results indicate that SFRP3 acts as a novel putative tumor suppressor gene in adenocarcinoma of the lung possibly regulating canonical WNT signaling.

Entities:  

Keywords:  DNA methylation; Lung cancer; NSCLC; SFRP3; WNT signaling

Mesh:

Substances:

Year:  2018        PMID: 27623992      PMCID: PMC5997146          DOI: 10.1080/15592294.2016.1229730

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  46 in total

Review 1.  A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling.

Authors:  Michael T Veeman; Jeffrey D Axelrod; Randall T Moon
Journal:  Dev Cell       Date:  2003-09       Impact factor: 12.270

Review 2.  Wnt signaling in lung cancer.

Authors:  Julien Mazieres; Biao He; Liang You; Zhidong Xu; David M Jablons
Journal:  Cancer Lett       Date:  2005-05-10       Impact factor: 8.679

Review 3.  Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung.

Authors:  M Mori; S K Rao; H H Popper; P T Cagle; A E Fraire
Journal:  Mod Pathol       Date:  2001-02       Impact factor: 7.842

4.  Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.

Authors:  E Noetzel; M Rose; E Sevinc; R-D Hilgers; A Hartmann; A Naami; R Knüchel; E Dahl
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

5.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

Review 6.  Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells.

Authors:  Dennis W Stacey
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

7.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.

Authors:  M Shtutman; J Zhurinsky; I Simcha; C Albanese; M D'Amico; R Pestell; A Ben-Ze'ev
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

8.  Methylation and loss of Secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasion.

Authors:  Elin J Ekström; Victoria Sherwood; Tommy Andersson
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

9.  Wnt5a is strongly expressed at the leading edge in non-melanoma skin cancer, forming active gradients, while canonical Wnt signalling is repressed.

Authors:  Celine Pourreyron; Louise Reilly; Charlotte Proby; Andrey Panteleyev; Colin Fleming; Kathleen McLean; Andrew P South; John Foerster
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

10.  Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.

Authors:  Erik Noetzel; Jürgen Veeck; Dieter Niederacher; Oliver Galm; Felicitas Horn; Arndt Hartmann; Ruth Knüchel; Edgar Dahl
Journal:  BMC Cancer       Date:  2008-05-30       Impact factor: 4.430

View more
  7 in total

1.  Overexpressed sFRP3 exerts an inhibitory effect on hepatocellular carcinoma via inactivation of the Wnt/β-catenin signaling pathway.

Authors:  Long Fang; Chun Gao; Ru-Xue Bai; Hui-Fen Wang; Shi-Yu Du
Journal:  Cancer Gene Ther       Date:  2020-09-26       Impact factor: 5.987

2.  Whole-Exome Sequencing of Germline Variants in Non-BRCA Families with Hereditary Breast Cancer.

Authors:  Yaxuan Liu; Hafdis T Helgadottir; Pedram Kharaziha; Jungmin Choi; Francesc López-Giráldez; Shrikant M Mane; Veronica Höiom; Carl Christofer Juhlin; Catharina Larsson; Svetlana Bajalica-Lagercrantz
Journal:  Biomedicines       Date:  2022-04-26

Review 3.  Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update.

Authors:  Pere Llinàs-Arias; Manel Esteller
Journal:  Open Biol       Date:  2017-09       Impact factor: 6.411

4.  Hypermethylation of MDFI promoter with NSCLC is specific for females, non-smokers and people younger than 65.

Authors:  Hongying Ma; Xiaoying Chen; Haochang Hu; Bin Li; Xiuru Ying; Cong Zhou; Jie Zhong; Guofang Zhao; Shiwei Duan
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

5.  Diagnosis value of aberrantly expressed microRNA profiles in lung squamous cell carcinoma: a study based on the Cancer Genome Atlas.

Authors:  Sheng Yang; Jing Sui; Geyu Liang
Journal:  PeerJ       Date:  2017-11-30       Impact factor: 2.984

6.  Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.

Authors:  Linjie Luo; Chao Liang
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

7.  Comprehensive Analysis of the Expression and Prognosis for SFRPs in Breast Carcinoma.

Authors:  Zeng-Hong Wu; You-Jing Zhang; Jian-Xin Yue; Tao Zhou
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.